FO
FOXO.US FOXO Technologies Inc.
- Market cap
- USD 280K
- P/E
- 0.0x
- P/B
- 0.28x
- ROE
- 1,353.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is FOXO.US undervalued?
Graham numberThe Graham number of FOXO Technologies Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FOXO Technologies Inc. fundamental analysis
No fundamental analysis for FOXO Technologies Inc. yet.
FOXO Technologies Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About FOXO Technologies Inc.
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. It operates through three segments: Healthcare, Life Science Services, and Labs. The company offers behavioral health services; ancillary services, including laboratory, radiology, respiratory, and pharmacy; insurance services; epigenetics diagnostics and interpretation services; and other services through its hospitals and behavioral health facilities. Its technology enable…
Full company profileFOXO Technologies Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
FOXO Technologies Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 63.0K | 120K | 511K | 145K | 4.05M | 16.4M | 19.8M |
| Gross Profit | 63.0K | 120K | 167K | 12.9K | 1.57M | 8.04M | 9.91M |
| Operating Income | -8.73M | -15.0M | -40.2M | -22.2M | -7.76M | -10.3M | 16.9M |
| EBITDA | -7.47M | -37.3M | -92.3M | -24.1M | -7.28M | -8.60M | 18.6M |
| Net Income | -8.65M | -38.5M | -95.3M | -26.5M | -12.4M | -12.4M | 13.4M |
| EPS | -43 | -66 | -84 | -6.27 | -0.85 | -0.05 | 0.14 |
| Balance Sheet | |||||||
| Total Assets | 9.42M | 30.3M | 35.4M | 725K | 41.7M | 44.6M | 45.9M |
| Total Liabilities | 704K | 55.5M | 28.7M | 14.8M | 36.4M | 33.5M | 45.0M |
| Shareholders' Equity | 8.72M | -25.2M | 6.71M | -14.1M | 5.32M | 11.1M | 988K |
| Cash & Short-term Investments | 8.12M | 6.86M | 5.52M | 38.0K | 68.3K | 207K | 58.4K |
| Total Debt | - | 32.2M | 3.14M | 4.20M | 14.3M | 11.0M | 20.7M |
| Cash Flow | |||||||
| Operating Cash Flow | -481K | -15.1M | -23.8M | -6.65M | -2.84M | -3.87M | -558K |
| Capital Expenditure | 5.00 | 242K | 1.87M | 3.00 | 4.00 | 62.0K | 16.0K |
| Free Cash Flow | -481K | -15.3M | -25.6M | -6.65M | -2.84M | -3.93M | -558K |
| Ratios | |||||||
| ROE | -99.2% | - | -1,420.0% | - | -233.0% | -111.5% | 1,353.4% |
| ROA | -91.8% | -127.0% | -269.0% | -3,648.3% | -29.7% | -27.9% | 29.1% |
| Net Profit Margin | -13,734.9% | -32,073.3% | -18,640.9% | -18,205.2% | -306.2% | -75.9% | 67.7% |
| Debt to Equity | - | - | 0.47x | - | 2.68x | 0.98x | 20.90x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
FOXO Technologies Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 3.38M | 0.80 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:3000 on Jul 1, 2026.
Who owns FOXO Technologies Inc.
- Insiders 0.00%
- Institutions 5.01%
- Public & others 94.99%
- Shares outstanding 1.66M
- Free float 1.57M
FOXO Technologies Inc. company profile
- Company name
- FOXO Technologies Inc.
- Ticker
- FOXO.US
- Exchange
- USA Stocks
- Listed since
- Jan 29, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 192
- Fiscal year end
- December
- Address
- 477 South Rosemary Ave., West Palm Beach, FL, United States, 33401
- Phone
- 612 800 0059
- Website
- foxotechnologies.com
About FOXO Technologies Inc.
FOXO Technologies Inc. operates as a healthcare services and technology company in the United States. It operates through three segments: Healthcare, Life Science Services, and Labs. The company offers behavioral health services; ancillary services, including laboratory, radiology, respiratory, and pharmacy; insurance services; epigenetics diagnostics and interpretation services; and other services through its hospitals and behavioral health facilities. Its technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for data analysis and processing, and quality checking for academia, healthcare, government, and pharmaceutical research customers. FOXO Technologies Inc. was founded in 2020 and is based in West Palm Beach, Florida.
FOXO Technologies Inc. management
5- Mr. Seamus LaganCEO, Interim CFO & Director · born 1969
- Ms. Celene Laurene Rattray Grant CPA, M.B.A.CFO and Principal Financial & Accounting Officer · born 1982
- Ms. Rebecca McGuckinMarketing Director
- Ms. Karen Taylor-BatesVice President of Human Resources
- Ms. Kristine DymondTreasurer